Six-Planet Solar System in Perfect Synchrony Discovered in Milky Way

This illustration provided by the European Space Agency shows an artist's rendering of the Cheops telescope in orbit above Earth. Astronomers have discovered six planets orbiting a bright nearby star in perfect rhythmic harmony. (European Space Agency via AP)
This illustration provided by the European Space Agency shows an artist's rendering of the Cheops telescope in orbit above Earth. Astronomers have discovered six planets orbiting a bright nearby star in perfect rhythmic harmony. (European Space Agency via AP)
TT

Six-Planet Solar System in Perfect Synchrony Discovered in Milky Way

This illustration provided by the European Space Agency shows an artist's rendering of the Cheops telescope in orbit above Earth. Astronomers have discovered six planets orbiting a bright nearby star in perfect rhythmic harmony. (European Space Agency via AP)
This illustration provided by the European Space Agency shows an artist's rendering of the Cheops telescope in orbit above Earth. Astronomers have discovered six planets orbiting a bright nearby star in perfect rhythmic harmony. (European Space Agency via AP)

Astronomers have discovered a rare in-sync solar system with six planets moving like a grand cosmic orchestra, untouched by outside forces since their birth billions of years ago.

The find, announced Wednesday, can help explain how solar systems across the Milky Way galaxy came to be. This one is 100 light-years away in the constellation Coma Berenices. A light-year is 5.8 trillion miles.

A pair of planet-hunting satellites — NASA’s Tess and the European Space Agency’s Cheops — teamed up for the observations.

None of the planets in perfect synchrony are within the star’s so-called habitable zone, which means little if any likelihood of life, at least as we know it.

“Here we have a golden target” for comparison, said Adrien Leleu of the University of Geneva, who was part of an international team that published the results in the journal Nature.

This star, known as HD 110067, may have even more planets. The six found so far are roughly two to three times the size of Earth, but with densities closer to the gas giants in our own solar system. Their orbits range from nine to 54 days, putting them closer to their star than Venus is to the sun and making them exceedingly hot.

As gas planets, they're believed to have solid cores made of rock, metal or ice, enveloped by thick layers of hydrogen, according to the scientists. More observations are needed to determine what's in their atmospheres.

This solar system is unique because all six planets move similar to a perfectly synchronized symphony, scientists said. In technical terms, it’s known as resonance that's “precise, very orderly,” said co-author Enric Palle of the Institute of Astrophysics of the Canary Islands.

The innermost planet completes three orbits for every two by its closest neighbor. It's the same for the second- and third-closest planets, and the third- and fourth-closest planets.

The two outermost planets complete an orbit in 41 and 54.7 days, resulting in four orbits for every three. The innermost planet, meanwhile, completes six orbits in exactly the time the outermost completes one.

All solar systems, including our own, are thought to have started out like this one, according to the scientists. But it's estimated only 1-in-100 systems have retained that synchrony, and ours isn't one of them. Giant planets can throw things off-kilter. So can meteor bombardments, close encounters with neighboring stars and other disturbances.

While astronomers know of 40 to 50 in-sync solar systems, none have as many planets in such perfect step or as bright a star as this one, Palle said.

The University of Bern’s Hugh Osborn, who was part of the team, was “shocked and delighted” when the orbital periods of this star system’s planets came close to what scientists predicted.

“My jaw was on the floor,” he said. “That was a really nice moment.”



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”